Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet.
Keitaro
K
Yokoyama
Ichiro
I
Ohkido
Takeo
T
Iwamoto
Mari
M
Ishida
Mitsuyoshi
M
Urashima
Tatsuo
T
Hosoya
D000368:Aged; D015415:Biomarkers / Q000097:blood; D057966:Calcimimetic Agents / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D000069449:Cinacalcet; D015536:Down-Regulation; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007674:Kidney Diseases / Q000097:blood / Q000150:complications / Q000628:therapy*; D008246:Lysophospholipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000097:blood; D016896:Treatment Outcome
D015415:Biomarkers; D057966:Calcimimetic Agents; D008246:Lysophospholipids; D009281:Naphthalenes; C060506:sphingosine 1-phosphate; D013110:Sphingosine; D000069449:Cinacalcet